PyInvesting

Market research

ARCH.V Arch Biopartners Inc

V CAD Healthcare

Latest close

0.88 —

As of Nov 19, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
62M
P/E ratio
Not available
Analyst target
Not available
Dividend yield
Not available
Beta
1.61

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

Arch Biopartners Inc is currently in a long term downtrend where the price is trading 4.9% below its 200 day moving average.

From a valuation standpoint, the stock is 15.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1182.1.

Arch Biopartners Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has dropped by 125.4% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 48.8% to $-710K since the same quarter in the previous year.

Based on the above factors, Arch Biopartners Inc gets an overall score of 0/5.